TW202120122A - 基於免疫記憶之新穎疾病治療及預防 - Google Patents

基於免疫記憶之新穎疾病治療及預防 Download PDF

Info

Publication number
TW202120122A
TW202120122A TW109127427A TW109127427A TW202120122A TW 202120122 A TW202120122 A TW 202120122A TW 109127427 A TW109127427 A TW 109127427A TW 109127427 A TW109127427 A TW 109127427A TW 202120122 A TW202120122 A TW 202120122A
Authority
TW
Taiwan
Prior art keywords
antigen
subject
cancer
cells
mentioned
Prior art date
Application number
TW109127427A
Other languages
English (en)
Chinese (zh)
Inventor
石井健
小林伸好
大平裕太
瀬戸孝一
Original Assignee
國立研究開發法人醫藥基盤・健康・營養研究所
日商志瑞亞新藥工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立研究開發法人醫藥基盤・健康・營養研究所, 日商志瑞亞新藥工業股份有限公司 filed Critical 國立研究開發法人醫藥基盤・健康・營養研究所
Publication of TW202120122A publication Critical patent/TW202120122A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109127427A 2019-08-13 2020-08-12 基於免疫記憶之新穎疾病治療及預防 TW202120122A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2019-148551 2019-08-13
JP2019148551 2019-08-13
JP2019047945 2019-12-06
TW108144810 2019-12-06
TW108144810 2019-12-06
WOPCT/JP2019/047945 2019-12-06

Publications (1)

Publication Number Publication Date
TW202120122A true TW202120122A (zh) 2021-06-01

Family

ID=74570356

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109127427A TW202120122A (zh) 2019-08-13 2020-08-12 基於免疫記憶之新穎疾病治療及預防

Country Status (5)

Country Link
US (1) US20220401545A1 (https=)
EP (1) EP4014988A4 (https=)
JP (2) JPWO2021029424A1 (https=)
TW (1) TW202120122A (https=)
WO (1) WO2021029424A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
US6015796A (en) * 1998-03-11 2000-01-18 Zeria Pharmaceutical Co., Ltd. Method for treating AIDS
US10722537B2 (en) * 2015-11-06 2020-07-28 Regents Of The University Of Minnesota Activation of resident memory T cells for cancer immunotherapy
CN108144810A (zh) 2017-12-27 2018-06-12 苏州华控注胶技术有限公司 一种用于注胶机定量出胶的压力装置
JP2019148551A (ja) 2018-02-28 2019-09-05 株式会社東芝 構造物の内部検査装置、構造物の内部検査方法

Also Published As

Publication number Publication date
EP4014988A1 (en) 2022-06-22
WO2021029424A1 (ja) 2021-02-18
EP4014988A4 (en) 2023-11-29
US20220401545A1 (en) 2022-12-22
JPWO2021029424A1 (https=) 2021-02-18
JP2025138799A (ja) 2025-09-25

Similar Documents

Publication Publication Date Title
Li et al. Gut microbiome and cancer immunotherapy
US12414988B2 (en) Th1-inducing adjuvant comprising combination of different nucleic acid adjuvants and use of same
Coleman et al. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
Hall et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses
JP2023063330A (ja) 処置方法
Ning et al. β‐glucan restores tumor‐educated dendritic cell maturation to enhance antitumor immune responses
Downey et al. MAIT cells as attractive vaccine targets
JP2022002511A (ja) 病原体からの免疫原性抗原同定および臨床的有効性との相関
Esposito et al. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children
van Twillert et al. Waning and aging of cellular immunity to Bordetella pertussis
Fukuyama et al. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice
McElhaney Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response
JP2025138799A (ja) 免疫記憶に基づく新規疾患治療および予防
KR20250155052A (ko) 장내 미생물총 개체군 조절, 장내 미생물 불균형의 치료 및 질환 예방을 위한 조성물, 및 이의 제조 및 사용 방법
JP2025146968A (ja) がん治療方法及び医薬
Semple et al. Induction of granulysin and perforin cytolytic mediator expression in 10‐week‐old infants vaccinated with BCG at birth
Stefanetti et al. Impact of the host microbiome on vaccine responsiveness: lessons learned and future perspective
Zhang et al. Macrophages exploit the mannose receptor and JAK-STAT1-MHC-II pathway to drive antigen presentation and the antimycobacterial immune response after BCG vaccination: MR deficiency impairs BCG immune response
WO2022011271A2 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
CN114641309A (zh) 基于免疫记忆的新型的疾病治疗及预防
TW202245834A (zh) 基於控制細胞性免疫之新穎方法之新穎治療及預防
Yamaya et al. ARNAX, but not conventional adjuvants, alum and squalene, induces antigen-specific CD8+ T cell proliferation in vaccination with influenza split vaccine
Granadillo et al. The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response
Su et al. Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model
US20240376431A1 (en) Microbial cross-reactive antigens for use in the stimulation of t-cells